DRTS · Alpha Tau Medical Ltd. Ordinary Shares
View on chartInsiders & Stakes
No transactions found.
Transaction History
No transactions found.
No transactions found.
No transactions found.
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Alpha Tau Medical Gains Analyst Support as GBM Treatment Shows Promise
Alpha Tau Medical is drawing increased attention from analysts as the company approaches year-end with potential breakthrough data for its Alpha DaRT treatment in glioblastoma. Barclays raised its price target to $30, notably above the current analyst consensus of $14.40. Separately, Alpha Tau completed enrollment for its pancreatic cancer pilot study, suggesting progress across its clinical pipeline. The company is also scheduled to present at major investor conferences in September.
Alpha Tau Medical Gains Analyst Support as GBM Treatment Shows Promise. Alpha Tau Medical is drawing increased attention from analysts as the company approaches year-end with potential breakthrough data for its Alpha DaRT treatment in glioblastoma. Barclays raised its price target to $30, notably above the current analyst consensus of $14.40. Separately, Alpha Tau completed enrollment for its pancreatic cancer pilot study, suggesting progress across its clinical pipeline. The company is also scheduled to present at major investor conferences in September.